Siemens Healthineers has announced plans to change its name to Healthineers, with migration of this new brand set to begin with a three-year transition period in early 2027. In a separate press release, Siemens Healthineers also announced intentions to establish its in-vitro diagnostics business as a standalone company named Olyrian Diagnostics, with these two transitions set to take place in parallel.
The transition to Healthineers, a press release states, is “the next step in the company’s evolution to a fully standalone leading healthcare company”.
“This is the logical next step in a journey we started years ago—and one that has proven hugely successful,” said Roland Busch, president and chief executive officer (CEO) of Siemens. “Siemens Healthineers has grown from its Siemens roots into a global leader in its own right. It is only natural that this evolution is reflected clearly in how the company presents itself to the outside world. For Siemens, this sharpens our profile as the company that scales AI [artificial intelligence] in the real world. Our unique ability to combine the real and digital worlds makes this possible, accelerating profitable growth.”
“Siemens is where we have come from and remains an important and treasured part of our heritage,” added Bernd Montag, president and CEO of Siemens Healthineers. “Healthineers is who we are—engineers and pioneers in healthcare. After the deconsolidation from Siemens, we will write the next chapters of our journey in the Healthineers name and will continue pioneering breakthroughs in healthcare for everyone, everywhere, sustainably.”
Siemens plans to deconsolidate Siemens Healthineers in 2027 by way of a spin-off. The spin-off will be submitted for shareholder approval of both companies at their annual shareholders’ meetings in February next year. The company name change to Healthineers needs to be approved at the Siemens Healthineers annual shareholders’ meeting, the release also details.
The brand transition is expected to start following the entry of Healthineers into the German Commercial Register, which will complete the spin-off and deconsolidation from Siemens. A brand transition agreement has been agreed for a period of three years after deconsolidation to allow for “a smooth transition”, including the re-registration of legal entities and products.
Siemens Healthineers has also announced that it has initiated the carve-out process for its in-vitro diagnostics business, marking an “important step” toward establishing a standalone company that will operate as Olyrian Diagnostics. This new name will be rolled out in stages, with the transition expected to be completed by mid-2028.
According to a press release, Olyrian “defines the path forward with a clear purpose”: powering human potential at the heart of care. This new name and purpose reflect an “unwavering commitment” to people at the heart of healthcare, and the company’s focus on advancing diagnostics from the laboratory to the point of care, the release adds.
“Technology creates possibilities, but people turn those possibilities into better care and outcomes for patients,” commented Sharon Bracken, head of diagnostics for Siemens Healthineers. “Every day, at the heart of care in the laboratory, we support care teams as they provide critical answers patients need. Whether someone is running a test, interpreting a result, or deciding what happens next, informed and connected workflows help drive efficiency and empower a more comprehensive understanding of patient health. Olyrian Diagnostics is how we’ll define our next chapter. We’re proud of our history and excited by our future.”
